Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-γ/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection

Vaccine

Volumn 28, Issue 31, 2010, Pages 5135-5144

  Cummings, James F ^a   Spring, Michele D ^a   Schwenk, Robert J ^a   Ockenhouse, Christian F ^a   Kester, Kent E ^a   Polhemus, Mark E ^a   Walsh, Douglas S ^a   Yoon, In Kyu ^a,j   Prosperi, Christine ^a   Juompan, Laure Y ^a   Lanar, David E ^a   Krzych, Urszula ^a   Hall, B Ted ^a   Ware, Lisa A ^a   Stewart, V Ann ^a,i   Williams, Jack ^a   Dowler, Megan ^a   Nielsen, Robin K ^a   Hillier, Collette J ^a,h   Giersing, Birgitte K ^b,f   Dubovsky, Filip ^b   Malkin, Elissa ^b,g   Tucker, Kathryn ^c   Dubois, Marie Claude ^d   Cohen, Joe D ^d   Ballou, W Ripley ^d,e   Heppner, G ^a   more..

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b PATH Malaria Vaccine Initiative   (United States)

^c University of Iowa   (United States)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^e BILL AND MELINDA GATES FOUNDATION   (United States)

^f Emergent Biosolutions   (United Kingdom)

^g MEDIMMUNE   (United States)

^h Arana Therapeutics Ltd   (Australia)

ⁱ U S ARMY   (United States)

^j Armed Forces Research Institute of Medical Sciences San Francisco   (United States)

more..

Author keywords

Liver Stage Antigen; Malaria vaccine; Plasmodium falciparum

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; RECOMBINANT ANTIGEN; RECOMBINANT LIVER STAGE ANTIGEN 1; UNCLASSIFIED DRUG; IL2 PROTEIN, HUMAN; IMMUNOLOGICAL ADJUVANT; LIVER STAGE-SPECIFIC ANTIGEN, PLASMODIUM; MALARIA VACCINE; PARASITE ANTIGEN; PROTOZOON ANTIBODY; RECOMBINANT PROTEIN;

ADULT; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; EXPERIMENTAL INFECTION; FEMALE; HUMAN; IMMUNIZATION; LOW DRUG DOSE; MALARIA; MALE; PARASITEMIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; ANTIBODY PRODUCTION; BLOOD; CELLULAR IMMUNITY; HUMORAL IMMUNITY; IMMUNOLOGY; MALARIA, FALCIPARUM; RANDOMIZED CONTROLLED TRIAL; SPOROZOITE; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, PROTOZOAN; ANTIBODY FORMATION; ANTIGENS, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; INTERLEUKIN-2; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PARASITEMIA; PLASMODIUM FALCIPARUM; RECOMBINANT PROTEINS; SPOROZOITES; YOUNG ADULT;

EID: 77954760139     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.046     Document Type: Article

References (36)

1. Connelly M., King C.L., Bucci K., Walters S., Genton B., Alpers M.P., et al. T-cell immunity to peptide epitopes of liver-stage antigen 1 in an area of Papua New Guinea in which malaria is holoendemic. Infect Immun 1997, 65:5082-5087.
2. Domarle O., Migot-Nabias F., Mvoukani J.L., Lu C.Y., Nabias R., Mayombo J., et al. Factors influencing resistance to reinfection with Plasmodium falciparum. Am J Trop Med Hyg 1999, 61(6):926-931.
3. Hill A.V., Elvin J., Willis A.C., Aidoo M., Allsopp C.E., Gotch F.M., et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992, 360:434-439.
4. John C.C., Moormann A.M., Sumba P.O., Ofulla A.V., Pregibon D.C., Kazura J.W. Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria. Infect Immun 2004, 72:5135-5142.
5. Kurtis J.D., Lanar D.E., Opollo M., Duffy P.E. Interleukin-10 responses to liver-stage antigen 1 predict human resistance to Plasmodium falciparum. Infect Immun 1999, 67:3424-3429.
6. Luty A.J., Lell B., Schmidt-Ott R., Lehman L.G., Luckner D., Greve B., et al. Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J Infect Dis 1999, 179:980-988.
7. Luty A.J., Lell B., Schmidt-Ott R., Lehman L.G., Luckner D., Greve B., et al. Parasite antigen-specific interleukin-10 and antibody responses predict accelerated parasite clearance in Plasmodium falciparum malaria. Eur Cytokine Netw 1998, 9:639-646.
8. Krzych U., Lyon J.A., Jareed T., Schneider I., Hollingdale M.R., Gordon D.M., et al. T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens. J Immunol 1995, 155:4072-4077.
9. Fidock D.A., Gras-Masse H., Lepers J.P., Brahimi K., Benmohamed L., Mellouk S., et al. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. J Immunol 1994, 153:190-204. [Erratum in: J Immunol 1994; 153:5347].
10. Yang C., Shi Y.P., Udhayakumar V., Alpers M.P., Povoa M.M., Hawley W.A., et al. Sequence variations in the non-repetitive regions of the liver stage-specific antigen-1 (LSA-1) of Plasmodium falciparum from field isolates. Mol Biochem Parasitol 1995, 71:291-294.
11. Hollingdale M.R., Aikawa M., Atkinson C.T., Ballou W.R., Chen G.X., Li J., et al. Non-CS pre-erythrocytic protective antigens. Immunol Lett 1990, 25:71-76.
12. Hillier C.J., Ware L.A., Barbosa A., Angov E., Lyon J.A., Heppner D.G., et al. Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum. Infect Immun 2005, 73:2109-2115.
13. Brando C., Ware L.A., Freyberger H., Kathcart A., Barbosa A., Cayphas S., et al. Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A. Infect Immun 2007, 75:838-845.
14. Pichyangkul S., Kum-Arb U., Yongvanitchit K., Limsalakpetch A., Gettayacamin M., Lanar D.E., et al. Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates. Infect Immun 2008, 76:229-238.
15. Chulay J.D., Schneider I., Cosgriff T.M., Hoffman S.L., Ballou W.R., Quakyi I.A., et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg 1986, 35:66-68.
16. Kester K.E., Cummings J.F., Ockenhouse C.F., Nielsen R., Hall B.T., Gordon D.M., et al. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine 2008, 26:2191-2202.
17. Krzych U., Guebre-Xabier M., Schwenk R. Malaria and the liver. Tolerance and immunity to attenuated plasmodia sporozoites. The liver: immunobiology, pathology, and host defense 1999, 163-195. Wiley-Less. N. Crisp (Ed.).
18. Appay V., van Lier R.A., Sallusto F., Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008, 73:975-983.
19. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13:843-850.
20. Andersen E., Jones T.R., Purnomo, Masbar S., Wiady I., Tirtolusumo S., et al. Assessment of age-dependent immunity to malaria in transmigrants. Am J Trop Med Hyg 1997, 56:647-649.
21. Renia L., Marussig M.S., Grillot D., Pied S., Corradin G., Miltgen F., et al. In vitro activity of CD4+ and CD8+ T lymphocytes from mice immunized with a synthetic malaria peptide. Proc Natl Acad Sci USA 1991, 88:7963-7967.
22. Renia L., Grillot D., Marussig M., Corradin G., Miltgen F., Lambert P.H., et al. Effector functions of circumsporozoite peptide-primed CD4+ T cell clones against Plasmodium yoelii liver stages. J Immunol 1993, 150:1471-1478.
23. Sun P., Schwenk R., White K., Stoute J.A., Cohen J., Ballou W.R., et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol 2003, 171:6961-6967.
24. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CFO, Krzych U, Moris P, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naïve adults; safety, efficacy and immunologic associates of protection. JID; in press.
25. Badovinac V.P., Porter B.B., Harty J.T. CD8+ T cell contraction is controlled by early inflammation. Nat Immunol 2004, 5:809-817.
26. Trinchieri G. Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med 2007, 204:239-243.
27. Collins W.E., Sullivan J.S., Williams A., Nace D., Williams T., Galland G.G., et al. Aotus nancymaae as a potential model for the testing of anti-sporozoite and liver stage vaccines against Plasmodium falciparum. Am J Trop Med Hyg 2006, 74:422-424.
28. Kurtis J.D., Hollingdale M.R., Luty A.J., Lanar D.E., Krzych U., Duffy P.E. Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-NRC vaccine. Trends Parasitol 2001, 17:219-223.
29. Ockenhouse C.F., Sun P.F., Lanar D.E., Wellde B.T., Hall B.T., Kester K., et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998, 177:1664-1673.
30. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003, 9:729-735.
31. Stephenson J. Defective adenoviruses as novel vaccines for the Flaviviridae. Clin Diagn Virol 1998, 10:187-194.
32. Vandepapeliere P., Horsmans Y., Moris P., Van Mechelen M., Janssens M., Koutsoukos M., et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008, 26:1375-1386.
33. Krzych U., Schwenk R. The dissection of CD8 T cells during liver-stage infection. Curr Topics Micro Immunol 2005, 297:1-24.
34. Wang R., Richie T.L., Baraceros M.F., Rahardjo N., Gay T., Banania J.G., et al. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infect Immun 2005, 73:2863-2872.
35. Stewart V.A., McGrath S.M., Dubois P.M., Pau M.G., Mettens P., Shott J., et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS.S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect Immun 2007, 75:2283-2290.
36. Rodríguez A., Goudsmit J., Companjen A., Mintardjo R., Gillissen G., Tax D., et al. Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1. Infect Immun 2008, 76:1709-1718.